Home/MEKanistic Therapeutics/Hagop Youssoufian, MD

HY

Hagop Youssoufian, MD

Chief Medical Advisor

MEKanistic Therapeutics

Therapeutic Areas

MEKanistic Therapeutics Pipeline

Drug	Indication	Phase
MTX-531	PIK3CA-mutant solid tumors (e.g., head and neck, breast, lung, gastrointestinal)	Preclinical

Leadership Team at MEKanistic Therapeutics

Chief Executive Officer

Judith Leopold, PhD

Chief Scientific Officer

Christopher Whitehead, PhD, MBA

Chief Operating Officer

View full MEKanistic Therapeutics profile